Evidence quality 4.63/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 5/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 3/5
- D8 Caveat completeness
- 5/5
● your factors — click this risk ▾ to reveal
- Your factors
≈ As likely as
Perceived
Sickle cell disease occupies a peculiar informational niche: well known as a textbook example of Mendelian genetics, poorly understood in terms of actual prevalence. Most Americans can recall the phrase "sickle cell" from a biology class but would struggle to distinguish trait from disease or estimate how many people are affected. Among Black Americans, awareness tends to be higher but still imprecise — many know someone with the trait but fewer grasp the 1-in-365 birth prevalence of the disease itself. No large-scale survey isolates "fear of having sickle cell disease" as a distinct item, so the perceived estimate here relies on editorial judgment informed by public-health literacy research.
Rough estimate: generally underestimated by the broad public; somewhat better known in affected communities
Source: editorial intuition, not polled
Actual
~1 in 365 Black or African American births in the US
Black or African American newborns in the US
Show derivation
CDC reports SCD occurs in approximately 1 out of every 365 Black or African American births. The 2016–2020 Sickle Cell Data Collection program across 11 states found a crude prevalence of 28.54 per 10,000 non-Hispanic Black newborns (approximately 1 in 350), broadly consistent with the established 1-in-365 figure. Because SCD is a genetic condition present at birth, the "lifetime probability" is simply the birth prevalence for the affected subgroup: 1/365 ≈ 0.00274. This is not annualized or compounded — it is the probability that a Black American newborn will have SCD. For the overall US population (all races), the birth prevalence is approximately 4.83 per 10,000 (1 in 2,070). The normalized figure here uses the subgroup-specific rate because the condition is overwhelmingly concentrated in this population.
Caveats: Sickle cell disease is a genetic condition, not an acquired risk — the "probabil…
Sickle cell disease is a genetic condition, not an acquired risk — the "probability" here is birth prevalence, not an annual hazard rate. It is determined entirely by parental genotype. The 1-in-365 figure applies specifically to Black or African American newborns; for the overall US population (all races), birth prevalence is roughly 1 in 2,070. Sickle cell trait (carrying one copy of the gene) is far more common — about 1 in 13 Black Americans — but trait carriers generally do not develop the disease. SCD prevalence also varies by specific ancestry within the African diaspora, with higher rates among those with West African heritage. Life expectancy for SCD patients has improved significantly with hydroxyurea and other therapies but remains substantially below the general population average.
Related risks
Other risks on similar themes — for exploring related fears.
Spinal cord injury
What are the odds of suffering a traumatic spinal cord injury that causes paralysis?
Childhood cancer diagnosis
What are the odds of a child being diagnosed with cancer before age 20?
Unsafe imported products
What are the odds of being harmed by an unsafe imported consumer product?
Counterfeit medicine
What are the odds of being harmed or killed by a counterfeit or substandard medicine?
Pick challenger
About 1 in every 365 Black or African American babies born in the United States has sickle cell disease, a genetic blood disorder caused by inheriting two copies of the hemoglobin S gene. That translates to roughly 100,000 affected Americans at any given time, making SCD the most common inherited blood disorder in the country. For comparison, cystic fibrosis — the genetic condition most familiar to white Americans — has a birth prevalence about ten times lower among its primary demographic.
The gap between textbook familiarity and practical understanding is wide. Most adults can identify “sickle cell” as something they learned about in biology, but few can distinguish trait from disease. About 1 in 13 Black Americans carry the sickle cell trait (one gene copy) and are generally asymptomatic, while the 1-in-365 who inherit two copies face chronic anemia, pain crises, organ damage, and a life expectancy roughly 20 years shorter than the national average. The trait’s persistence is itself a genetics lesson: heterozygous carriers have historically enjoyed partial protection against malaria, a textbook case of balancing selection that kept the gene circulating in populations with West African ancestry.
The 1-in-365 figure is a subgroup-specific birth prevalence, not a universal US rate. For Hispanic Americans, birth prevalence drops to roughly 1 in 16,300; for non-Hispanic white Americans, SCD is vanishingly rare. Within the Black American population, prevalence varies further by specific ancestry — West African heritage correlates with higher carrier rates. And because SCD is congenital, it is not a risk you accumulate over time like a car crash or a cancer diagnosis; either you have it at birth or you do not.
Related tidbits
Sickle cell disease occurs in about 1 in 365 Black or African American births in the US. Painful vaso-occlusive crises are the recurring hallmark; the condition is far better known inside affected communities than out.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
1/3 sources independently verified verbatim against the cited source
-
[1] Centers for Disease Control and Prevention — Data and Statistics on Sickle Cell Disease
Data and Statistics on Sickle Cell Disease- Statistic
SCD affects approximately 100,000 Americans; occurs in about 1 in 365 Black or African American births and 1 in 16,300 Hispanic American births- Excerpt
“"SCD affects approximately 100,000 Americans. SCD occurs among about 1 out of every 365 Black or African American births. SCD occurs among about 1 out of every 16,300 Hispanic-American births. Sickle cell trait (SCT) occurs among about 1 in 13 Black or African American babies." ”
- Source data from
- 2024-05-15
- Accessed
- 2026-04-18 · archived copy
- Calculation
- CDC reports 1 in 365 Black/African American births have SCD. This yields a birth prevalence of 1/365 ≈ 0.002740. The 100,000 affected Americans figure is consistent with ~45 million Black Americans × 0.00274 prevalence, accounting for reduced life expectancy in SCD patients (median survival ~54 years vs ~77 years general population). No annualization needed — SCD is a congenital condition, so birth prevalence equals lifetime prevalence for the subgroup.
-
[2] CDC Morbidity and Mortality Weekly Report — Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability — Sickle Cell Data Collection Program, 11 States, 2016–2020
Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability — Sickle Cell Data Collection Program, 11 States, 2016–2020- Statistic
SCD birth prevalence of 28.54 per 10,000 (1 in 350) among non-Hispanic Black newborns across 11 states, 2016–2020- Excerpt
“"During 2016–2020, a total of 3,305 confirmed SCD cases were identified among newborns in 11 states. The crude SCD birth prevalence was 4.83 per 10,000 live births overall and 28.54 per 10,000 among non-Hispanic Black newborns." ”
- Source data from
- 2024-03-28
- Accessed
- 2026-04-18 · archived copy
- Calculation
- The MMWR study uses newborn screening data from 11 states participating in the Sickle Cell Data Collection program. The non-Hispanic Black birth prevalence of 28.54 per 10,000 equals 1 in 350, slightly higher than the traditionally cited 1 in 365. The difference likely reflects improved screening sensitivity and updated population denominators. The overall US birth prevalence of 4.83 per 10,000 (1 in 2,070) reflects dilution across all racial/ethnic groups. Both figures are consistent within expected variation.
-
[3] American Journal of Preventive Medicine — Population estimates of sickle cell disease in the U.S. Verified
Population estimates of sickle cell disease in the U.S.- Statistic
Estimated US SCD population of 72,000–98,000 (mortality-corrected), may approach 100,000 (2008)- Excerpt
“"National SCD population estimates ranged from 104,000 to 138,900, based on birth-cohort disease prevalence, but from 72,000 to 98,000 when corrected for early mortality. The number of individuals with SCD in the U.S. may approach 100,000, even when accounting for the effect of early mortality on estimations." ”
- Source data from
- 2010-06-01
- Accessed
- 2026-04-18 · archived copy
- Verification
- Excerpt independently re-fetched and confirmed word-for-word against the cited source during our grounding audit.
- Calculation
- Hassell (2010) used newborn screening data and survival estimates to compute population prevalence. The mortality-corrected estimate for 2008 was 72,000–98,000 (104,000–138,900 before correcting for early mortality), and the paper concludes the true number "may approach 100,000." This is broadly consistent with the current CDC figure of ~100,000 affected Americans, reflecting improved survival (hydroxyurea, penicillin prophylaxis, transfusion therapy) and immigration from SCD-prevalent regions. This source supports the ~100,000-prevalence headline; the 1-in-365 birth prevalence is cited separately to CDC newborn-screening data above.